Intermittent Fasting and Brain Health: The Evidence

Intermittent fasting and brain health is a growing area of scientific interest, with researchers exploring how periods of fasting may influence cognition, neuroinflammation, and long-term neurological resilience. Biological mechanisms such as increased brain-derived neurotrophic factor (BDNF), enhanced autophagy, and a metabolic shift towards ketone production have all been proposed as pathways through which fasting might benefit the brain. However, much of the evidence comes from animal studies or small human trials, and robust clinical conclusions remain limited. This article explains what the current science shows, what UK guidance says, who should exercise caution, and how to approach fasting safely if you have a neurological condition.

What does intermittent fasting actually do to your brain?

Intermittent fasting may increase BDNF, reduce neuroinflammation, and promote a metabolic shift to ketones, but most mechanistic evidence comes from animal models and robust human clinical conclusions remain limited.

Intermittent fasting triggers several biological processes that researchers believe may influence brain structure and function. These include increased production of brain-derived neurotrophic factor (BDNF), reduced neuroinflammation, and enhanced autophagy, the cellular process by which the body clears damaged proteins. During a fasting period, the body shifts from using glucose as its primary fuel source towards producing ketone bodies, which can cross the blood-brain barrier and provide an alternative energy substrate for neurons.^[5] Some researchers propose that this metabolic switch may support neuronal resilience and reduce oxidative stress, though this remains an area of active investigation.

BDNF is particularly relevant here. This protein supports the survival of existing neurons and encourages the growth of new ones, a process called neurogenesis, which is most active in the hippocampus, the region central to memory and learning. Animal studies have consistently shown that caloric restriction and intermittent fasting raise BDNF levels.^[1][2] Human data are more limited and mixed: where effects have been reported, effect sizes tend to be small and context-dependent, so these findings should not be directly extrapolated from animal models without caution. Brain-specific autophagy upregulation during routine intermittent fasting in humans is not yet established and is best understood as a hypothesis arising from preclinical work.

Intermittent fasting also appears to influence the hypothalamic-pituitary axis and circadian rhythm regulation, both of which have downstream effects on mood, cognition, and sleep quality, though robust human evidence for these specific brain-related effects remains limited. It is also worth noting that in the early stages of fasting, some people experience transient impairment in concentration or mood before adaptation occurs.

Common fasting protocols studied in humans include the 16:8 method (16 hours fasting, 8 hours eating), the 5:2 approach (five days of normal eating, two days of significant caloric restriction), and alternate-day fasting. Each protocol produces somewhat different metabolic and hormonal responses, and the brain-related effects may vary accordingly. Most mechanistic evidence in this area comes from animal models or small human studies, and robust clinical conclusions remain limited.

The evidence so far: what UK research and NICE guidance say

NICE has not recommended intermittent fasting for any neurological or psychiatric condition, and existing human trials show considerable heterogeneity with no high-quality long-term randomised controlled trial evidence.

Current evidence suggests that intermittent fasting may offer modest cognitive and neuroprotective benefits in some populations, but NICE has not issued specific guidance recommending intermittent fasting as a therapeutic intervention for any neurological or psychiatric condition. NICE guidance on mid-life approaches to delay or prevent dementia (NG16) and on dementia assessment, management and support (NG97) both acknowledge the role of diet and lifestyle, but neither endorses any particular fasting protocol for brain health outcomes.^[6] This reflects the reality that high-quality, long-term randomised controlled trials in humans are still limited, and existing studies show considerable heterogeneity in design, duration, and outcome measures.

Several UK-based research groups have contributed to this field, exploring how dietary patterns, including time-restricted eating, affect inflammatory markers, insulin sensitivity, and cognitive performance. A 2022 study published in Cell Metabolism examined time-restricted eating and found improvements in several cardiometabolic markers; cognitive endpoints were not the primary focus of that study, and its findings should be interpreted accordingly.^[8]

For conditions such as Alzheimer's disease and Parkinson's disease, preclinical data are more encouraging than clinical trial results. Ketone-based metabolism, promoted by fasting, has been explored as a potential adjunct in early Alzheimer's research, given that glucose metabolism in the brain is impaired in that condition. However, there is currently no specific NHS recommendation for intermittent fasting as a treatment or prevention strategy for dementia.

For weight management, where there is an indirect link to brain health through reduced cardiovascular risk and improved insulin sensitivity, NICE supports a range of dietary approaches as part of a broader weight-management plan. Intermittent fasting is one option a prescriber may consider in this context. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where such options may be discussed where clinically appropriate.

Who should be cautious about fasting for brain health?

People with eating disorders, type 1 diabetes, epilepsy, those on lithium or insulin, pregnant or breastfeeding women, and underweight individuals face meaningful risks and should not fast without medical supervision.

Intermittent fasting is not appropriate for everyone, and certain groups face meaningful risks that outweigh potential brain health benefits. People with a history of eating disorders, including anorexia nervosa, bulimia nervosa, or binge eating disorder, should avoid fasting protocols without specialist psychiatric and dietetic supervision, as structured food restriction can trigger or worsen disordered eating behaviours.

Individuals with type 1 diabetes or those taking insulin or sulfonylureas for type 2 diabetes face a risk of hypoglycaemia during fasting periods.^[15] Hypoglycaemia itself is harmful to the brain, causing impaired concentration, confusion, and, in severe cases, seizures or loss of consciousness. Anyone in this group should speak to their GP or diabetes team before making any significant dietary change, and should have a pre-agreed plan for glucose monitoring and any necessary dose adjustment.

People who are underweight (BMI below 18.5) or who have experienced recent unintentional weight loss should avoid intermittent fasting and seek medical assessment before making any dietary changes.

People who experience migraines should be aware that prolonged fasting is a recognised trigger for migraine attacks in some individuals.^[10] Those with recurrent migraines are advised to discuss any fasting plan with their GP before starting.

People living with epilepsy require particular care. While the ketogenic diet, a related but distinct dietary approach, is used therapeutically in some drug-resistant epilepsy cases under specialist supervision, intermittent fasting is not the same intervention and should not be self-initiated as a seizure management strategy.^[11][12] Similarly, those taking mood-stabilising medications such as lithium, or antiepileptic drugs used for psychiatric conditions, should be aware that fasting can alter drug absorption and plasma levels. For example, lithium levels are sensitive to changes in fluid and sodium intake, which fasting may affect; medication doses should never be adjusted without prescriber input.

Pregnant and breastfeeding women should not follow intermittent fasting protocols, as adequate and consistent nutrition is essential for foetal and infant development.^[14] Older adults, particularly those at risk of sarcopenia or malnutrition, and children and adolescents, should also avoid fasting without medical guidance. If you are unsure whether fasting is safe for you, speak to your GP in the first instance rather than self-prescribing a protocol based on online information.

How to try intermittent fasting safely if you have a neurological condition

Always consult your GP or specialist neurologist before starting intermittent fasting, begin with a modest 12-hour eating window, monitor symptoms closely, and seek urgent care if new focal neurological symptoms develop.

People with a neurological condition who wish to explore intermittent fasting should always discuss this with their GP or specialist neurologist before making any changes to their diet or medication routine. This is especially important for those with Parkinson's disease, multiple sclerosis, or a history of stroke, where nutritional status, medication timing, and energy demands are closely managed as part of ongoing care.

If a clinician supports a trial of intermittent fasting, a gradual approach is generally safer than an abrupt change. Starting with a modest eating window, such as 12 hours, and extending it slowly over several weeks allows the body and brain to adapt without the risk of significant hypoglycaemia, fatigue, or cognitive impairment. Keeping a symptom diary, noting mood, concentration, sleep quality, and any neurological symptoms, can help both the individual and their clinical team assess whether the approach is beneficial or causing harm. Maintaining balanced nutrition during eating windows, with adequate protein, fibre, and micronutrient-rich foods, is important to reduce the risk of malnutrition, particularly in older adults.

Hydration is particularly important during fasting periods, as dehydration can worsen headaches, fatigue, and cognitive fog, symptoms that may be mistaken for fasting adaptation but could indicate an underlying problem. Electrolyte balance should also be considered, especially in those on diuretics or medications that affect kidney function; your GP or specialist can advise on whether additional monitoring is needed.

Key safety points to discuss with your GP or specialist include:

• Medication timing: Some neurological medications must be taken with food, and fasting windows may need to be adjusted accordingly.

• Monitoring: Regular review of symptoms and, where relevant, blood glucose or medication levels.

• Exit criteria: Agreeing in advance on which symptoms should prompt stopping the protocol and seeking review.

Seek urgent medical attention or call 999 immediately if you experience any of the following during a fasting period: sudden unilateral weakness or facial droop, speech disturbance, a sudden severe headache unlike any you have had before, acute confusion, new focal neurological symptoms, or a significant increase in seizure frequency. For new or worsening neurological symptoms that are not immediately life-threatening, contact your GP promptly.

If you are taking any medicines alongside a fasting plan and you suspect an adverse effect from a medicine, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Targeting BDNF as potential strategy to optimise brain health.
2. Effect of time restricted feeding on anthropometric measures, eating behavior, stress, serum levels of BDNF and LBP in overweight/obese women with food addiction: a randomized clinical trial.
3. A nonrandomized controlled clinical pilot trial on 8 wk of intermittent fasting (24 h/wk).
4. Effect of Calorie Restriction and Intermittent Fasting Regimens on Brain-Derived Neurotrophic Factor Levels and Cognitive Function in Humans: A Systematic Review.
5. Cerebral ketone body metabolism.
6. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16).
7. Dementia: assessment, management and support for people living with dementia and their carers (NG97).
8. Time-restricted eating and exercise training improve HbA1c and body composition in women with overweight/obesity: A randomized controlled trial.
9. Ketone bodies as a therapeutic for Alzheimer's disease.
10. Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
11. Ketogenic diets for drug-resistant epilepsy (NG217 evidence review).
12. Efficacy and safety of ketogenic diets in drug-resistant epilepsy: a systematic review and meta-analysis.
13. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
14. An updated review of popular dietary patterns during pregnancy and lactation: Trends, benefits, and challenges.
15. Hypoglycemia in children with type 1 diabetes: current issues and controversies.

Frequently Asked Questions